BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Novo  Nordisk  A/S  submitted  on  16  June  1997  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
NovoNorm, through the centralised procedure. After agreement by the CPMP on 20 March 1997, this 
medicinal  product  was  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EC)  2309/93  of 
22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  W. van der Giesen 
Co-Rapporteur: 
J. Genoux-Hames 
Licensing status 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 25 July 1997. 
The  Rapporteur's  first  assessment  report  was  circulated  to  all  CPMP  Members  on 
2 October 1997.  The  Co-rapporteur's  first  assessment  report  was  circulated  to  all  CPMP 
Members on 1 October 1997. 
During the meeting on 17-19 November the CPMP agreed on the consolidated list of questions 
to be sent to the company. The final consolidated list of questions was sent to the Company on 
21 November 1997. 
The company submitted the responses to the consolidated list of questions on 12 January 1998.  
The Rapporteur circulated the joint response assessment report on the company’s responses to 
the list of questions to all CPMP Members on 27 February 1997. 
The  company  submitted  further  response  to  issues  related  to  cardiovascular  safety  on 
23 February and 2 April 1998. 
During  the  CPMP  meeting  on  20  April  1998,  outstanding  issues  were  addressed  by  the 
applicant during a hearing before the CPMP.  
During the  meeting on 21-23 April 1998 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to NovoNorm on 22 April 1998. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission which adopted the corresponding Decisions on 17 August 1998. 
1/1  
EMEA 2004 
 
 
 
 
 
 
 
